Hirofumi Kogure

Real-World Efficacy and Safety of Gemcitabine, Cisplatin, Plus Immune Checkpoint Inhibitors in Biliary Tract Cancer: A Retrospective Analysis

Background: Based on the demonstrated survival benefits of gemcitabine plus cisplatin (GemCis) therapy in the TOPAZ-1 and KEYNOTE-966 trials, GemCis plus immune checkpoint inhibitor (ICI) therapy has become a standard first-line treatment for unresectable biliary tract cancer. Ho...